Anthony V Perruccio1,2, Matthew Got1,2, Suzanne Li1,2, Yang Ye1,2, Dafna D Gladman1,2, Vinod Chandran3,4. 1. From the Faculty of Medicine; Dalla Lana School of Public Health; Department of Surgery; Division of Rheumatology, Department of Medicine; Institute of Medical Science; Department of Laboratory Medicine and Pathobiology, University of Toronto; Health Care & Outcomes Research and Arthritis Program, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada. 2. A.V. Perruccio, PhD, Faculty of Medicine, and Dalla Lana School of Public Health, and Department of Surgery, University of Toronto, and Health Care & Outcomes Research and Arthritis Program, Krembil Research Institute, University Health Network; M. Got, MD, Faculty of Medicine, University of Toronto, Toronto, and Health Care & Outcomes Research and Arthritis Program, Krembil Research Institute, University Health Network; S. Li, MMath, Health Care & Outcomes Research and Arthritis Program, Krembil Research Institute, University Health Network; Y. Ye, MSc, Health Care & Outcomes Research and Arthritis Program, Krembil Research Institute, University Health Network; D.D. Gladman, MD, Faculty of Medicine, and Division of Rheumatology, Department of Medicine, and Institute of Medical Science, University of Toronto, and Health Care & Outcomes Research and Arthritis Program, Krembil Research Institute, University Health Network; V. Chandran, MD, PhD, Faculty of Medicine, and Division of Rheumatology, Department of Medicine, and Institute of Medical Science, and Department of Laboratory Medicine and Pathobiology, University of Toronto, and Health Care & Outcomes Research and Arthritis Program, Krembil Research Institute, University Health Network. 3. From the Faculty of Medicine; Dalla Lana School of Public Health; Department of Surgery; Division of Rheumatology, Department of Medicine; Institute of Medical Science; Department of Laboratory Medicine and Pathobiology, University of Toronto; Health Care & Outcomes Research and Arthritis Program, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada. vinod.chandran@uhnresearch.ca. 4. A.V. Perruccio, PhD, Faculty of Medicine, and Dalla Lana School of Public Health, and Department of Surgery, University of Toronto, and Health Care & Outcomes Research and Arthritis Program, Krembil Research Institute, University Health Network; M. Got, MD, Faculty of Medicine, University of Toronto, Toronto, and Health Care & Outcomes Research and Arthritis Program, Krembil Research Institute, University Health Network; S. Li, MMath, Health Care & Outcomes Research and Arthritis Program, Krembil Research Institute, University Health Network; Y. Ye, MSc, Health Care & Outcomes Research and Arthritis Program, Krembil Research Institute, University Health Network; D.D. Gladman, MD, Faculty of Medicine, and Division of Rheumatology, Department of Medicine, and Institute of Medical Science, University of Toronto, and Health Care & Outcomes Research and Arthritis Program, Krembil Research Institute, University Health Network; V. Chandran, MD, PhD, Faculty of Medicine, and Division of Rheumatology, Department of Medicine, and Institute of Medical Science, and Department of Laboratory Medicine and Pathobiology, University of Toronto, and Health Care & Outcomes Research and Arthritis Program, Krembil Research Institute, University Health Network. vinod.chandran@uhnresearch.ca.
Abstract
OBJECTIVE: The Psoriatic Arthritis Disease Activity Score (PASDAS) is a composite disease activity measure (range 0-10) for psoriatic arthritis (PsA). We aimed to validate a cutoff value of PASDAS that defines minimal disease activity (MDA) state, as well as to validate previously defined PASDAS cutoffs for low and high disease activity. METHODS: Patients were prospectively recruited from the University of Toronto PsA clinic according to a standard protocol, and variables necessary to complete the PASDAS and the MDA were collected. Receiver-operating characteristic (ROC) curve analysis determined the optimal PASDAS cutoff discriminating patients in MDA state from those not in MDA. Previously proposed PASDAS disease activity cutoff scores were validated by determining the proportion of patients requiring treatment escalation, a surrogate of active disease, in each of low, moderate, and high disease activity groups. RESULTS: One hundred seventy-eight patients [53.9% male, mean PASDAS 3.29 (SD 1.29), 47.8% in MDA] were recruited. ROC curve analysis identified a PASDAS score of 3.2 as the point that maximized the sensitivity and specificity for MDA based on 5 of 7 criteria (sensitivity 88%, specificity 92%, area under the curve 0.96). For MDA based on meeting 6 of 7 and 7 of 7 criteria, PASDAS scores of 2.6 and 2.1 maximized sensitivity and specificity, respectively. An increasing proportion of patients from low to moderate to high disease activity groups required treatment escalation, increasing from 8.1% to 42% to 67%, respectively. CONCLUSION: A PASDAS score < 3.2 reflects MDA. This study has externally validated PASDAS cutoff scores previously proposed to differentiate between low, moderate, and high disease activity.
OBJECTIVE: The Psoriatic Arthritis Disease Activity Score (PASDAS) is a composite disease activity measure (range 0-10) for psoriatic arthritis (PsA). We aimed to validate a cutoff value of PASDAS that defines minimal disease activity (MDA) state, as well as to validate previously defined PASDAS cutoffs for low and high disease activity. METHODS:Patients were prospectively recruited from the University of Toronto PsA clinic according to a standard protocol, and variables necessary to complete the PASDAS and the MDA were collected. Receiver-operating characteristic (ROC) curve analysis determined the optimal PASDAS cutoff discriminating patients in MDA state from those not in MDA. Previously proposed PASDAS disease activity cutoff scores were validated by determining the proportion of patients requiring treatment escalation, a surrogate of active disease, in each of low, moderate, and high disease activity groups. RESULTS: One hundred seventy-eight patients [53.9% male, mean PASDAS 3.29 (SD 1.29), 47.8% in MDA] were recruited. ROC curve analysis identified a PASDAS score of 3.2 as the point that maximized the sensitivity and specificity for MDA based on 5 of 7 criteria (sensitivity 88%, specificity 92%, area under the curve 0.96). For MDA based on meeting 6 of 7 and 7 of 7 criteria, PASDAS scores of 2.6 and 2.1 maximized sensitivity and specificity, respectively. An increasing proportion of patients from low to moderate to high disease activity groups required treatment escalation, increasing from 8.1% to 42% to 67%, respectively. CONCLUSION: A PASDAS score < 3.2 reflects MDA. This study has externally validated PASDAS cutoff scores previously proposed to differentiate between low, moderate, and high disease activity.